157 related articles for article (PubMed ID: 8339288)
1. Pharmacokinetics and metabolism of ifosfamide administered as a continuous infusion in children.
Boddy AV; Yule SM; Wyllie R; Price L; Pearson AD; Idle JR
Cancer Res; 1993 Aug; 53(16):3758-64. PubMed ID: 8339288
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of ifosfamide, 2- and 3-dechloroethylifosfamide in plasma and urine of cancer patients treated with a 10-day continuous infusion of ifosfamide.
Kaijser GP; Keizer HJ; Beijnen JH; Bult A; Underberg WJ
Anticancer Res; 1996; 16(5B):3247-57. PubMed ID: 8920799
[TBL] [Abstract][Full Text] [Related]
3. Influence of dose and infusion duration on pharmacokinetics of ifosfamide and metabolites.
Kerbusch T; Mathôt RA; Keizer HJ; Kaijser GP; Schellens JH; Beijnen JH
Drug Metab Dispos; 2001 Jul; 29(7):967-75. PubMed ID: 11408362
[TBL] [Abstract][Full Text] [Related]
4. Comparison of continuous infusion and bolus administration of ifosfamide in children.
Boddy AV; Yule SM; Wyllie R; Price L; Pearson AD; Idle JR
Eur J Cancer; 1995; 31A(5):785-90. PubMed ID: 7640054
[TBL] [Abstract][Full Text] [Related]
5. The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion.
Boddy AV; Cole M; Pearson AD; Idle JR
Cancer Chemother Pharmacol; 1995; 36(1):53-60. PubMed ID: 7720176
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of ifosfamide and some metabolites in children.
Kaijser GP; De Kraker J; Bult A; Underberg WJ; Beijnen JH
Anticancer Res; 1998; 18(3B):1941-9. PubMed ID: 9677448
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic modelling of ifosfamide administered by continuous infusion on 5 days at the dose of 6 g/m2.
Passe P; Delepine N; Arnaud P; Urien S; Delepine G; Traoré F; Desbois JC; Brion F
Anticancer Res; 1999; 19(1B):837-42. PubMed ID: 10216502
[TBL] [Abstract][Full Text] [Related]
8. Ifosfamide nephrotoxicity: limited influence of metabolism and mode of administration during repeated therapy in paediatrics.
Boddy AV; English M; Pearson AD; Idle JR; Skinner R
Eur J Cancer; 1996 Jun; 32A(7):1179-84. PubMed ID: 8758250
[TBL] [Abstract][Full Text] [Related]
9. Excretion kinetics of ifosfamide side-chain metabolites in children on continuous and short-term infusion.
Silies H; Blaschke G; Hohenlöchter B; Rossi R; Jürgens H; Boos J
Int J Clin Pharmacol Ther; 1998 May; 36(5):246-52. PubMed ID: 9629987
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, metabolism and clinical effect of ifosfamide in breast cancer patients.
Boddy AV; Proctor M; Simmonds D; Lind MJ; Idle JR
Eur J Cancer; 1995; 31A(1):69-76. PubMed ID: 7695982
[TBL] [Abstract][Full Text] [Related]
11. [High dose ifosfamide at 15 g/m2/cycle: a feasibility study in 10 patients].
Baranzelli MC; Pichon F; Gourmel B; N'Guyen M; Deligny N; Demaille MC
Bull Cancer; 1997 Feb; 84(2):141-6. PubMed ID: 9180836
[TBL] [Abstract][Full Text] [Related]
12. Studies on the human pharmacokinetics of isophosphamide (NSC-109724).
Allen LM; Creaven PJ; Nelson RL
Cancer Treat Rep; 1976 Apr; 60(4):451-8. PubMed ID: 1277221
[TBL] [Abstract][Full Text] [Related]
13. [Ifosfamide and the metabolites of side chain oxidation--excretion in urine in various pediatric therapeutic protocols].
Boos J; Welslau U; Ritter J; Blaschke G; Schellong G
Klin Padiatr; 1992; 204(4):299-305. PubMed ID: 1518269
[TBL] [Abstract][Full Text] [Related]
14. Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF: a pharmacokinetic study in advanced sarcoma patients. Swiss Group for Clinical Cancer Research (SAKK).
Cerny T; Leyvraz S; von Briel T; Küpfer A; Schaad R; Schmitz SF; Honegger P; Sessa C; Brunner J; Boddy AV
Ann Oncol; 1999 Sep; 10(9):1087-94. PubMed ID: 10572607
[TBL] [Abstract][Full Text] [Related]
15. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
Lorigan P; Verweij J; Papai Z; Rodenhuis S; Le Cesne A; Leahy MG; Radford JA; Van Glabbeke MM; Kirkpatrick A; Hogendoorn PC; Blay JY;
J Clin Oncol; 2007 Jul; 25(21):3144-50. PubMed ID: 17634494
[TBL] [Abstract][Full Text] [Related]
16. Cyclophosphamide and ifosfamide metabolites in the cerebrospinal fluid of children.
Yule SM; Price L; Pearson AD; Boddy AV
Clin Cancer Res; 1997 Nov; 3(11):1985-92. PubMed ID: 9815588
[TBL] [Abstract][Full Text] [Related]
17. Ifosfamide metabolism and pharmacokinetics (review).
Kaijser GP; Beijnen JH; Bult A; Underberg WJ
Anticancer Res; 1994; 14(2A):517-31. PubMed ID: 8017856
[TBL] [Abstract][Full Text] [Related]
18. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.
Perucca E; Cloyd J; Critchley D; Fuseau E
Epilepsia; 2008 Jul; 49(7):1123-41. PubMed ID: 18503564
[TBL] [Abstract][Full Text] [Related]
19. Variations in schedules of ifosfamide administration: a better understanding of its implications on pharmacokinetics through a randomized cross-over study.
Brain EG; Rezai K; Weill S; Gauzan MF; Santoni J; Besse B; Goupil A; Turpin F; Urien S; Lokiec F
Cancer Chemother Pharmacol; 2007 Aug; 60(3):375-81. PubMed ID: 17106751
[TBL] [Abstract][Full Text] [Related]
20. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
Beland FA
Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]